search
        Home > Projects > Cardiovascular diseases > Incoag    
Cancer
Cardiovascular diseases
Neurodegenerative diseases
Infection and immunity
Translational Research IT (TraIT)
 
 
 
03-06-2013 Newsitem: Dutch CTMM Incoag team performs Thrombosis tests on French mountain Mont Blanc (4808 meters)
 
 
 
Innovative Coagulation Diagnostics (INCOAG)
 
Principal Investigator Prof. Dr. H. ten Cate (Maastricht University Medical Center)
CTMM Program manager: Erna Erdtsieck-Ernste
 
The blood clotting system serves a vital role in the protection against bleeding in case of injury. However, in particular cases the blood clotting process can also be activated in response to internal injuries of the vascular system (for example, inflammation) in the absence of bleeding, which can result in the formation of an intravascular thrombus leading to thrombosis. Current tests to assess blood clotting tendencies, and hence the risk of thrombosis, are laboratory based and lack sensitivity. The INCOAG project aims to develop a set of state-of-the-art diagnostic tests that can be used in near-patient settings to estimate, more easily and more sensitively than is currently possible, the risk of venous or arterial thrombosis. These same tests will also be targeted at assessment of the efficacy of preventive and curative antithrombotic medications. These tests will take the form of acute marker assays that estimate actual clotting activity in the blood, and capacity assays that detect the capacity of the blood to clot. As a parallel exercise, the INCOAG project also aims to discover new types of thrombotic risk marker, possibly in the form of microRNA molecules.
 
 
Professor Ten Cate - Hugo ten Cate.jpg
Prof. Dr. H. ten Cate
“This is the first time that a concerted collaborative effort involving top Dutch researchers and industrial players is being undertaken to improve coagulation diagnostics! The combination of up to date translational research and state-of-the-art industrial technology provides a strong basis for establishing new diagnostic tests that may better detect the risk of thrombosis and may also be suited to monitoring a range of new antithrombotic drugs.”
Prof. Dr. Hugo ten Cate obtained his MD and PhD from the University of Amsterdam in 1987, followed by 15 years in research and clinical practice. In 2002 he was appointed Professor of Medicine for Clinical Thrombosis and Hemostasis at the Maastricht University. He is a board member of the Dutch Thrombosis Foundation and the Dutch Society for Thrombosis and Hemostasis Research (NVTH), and medical director of the Maastricht Thrombosis anticoagulation clinic. During his career, he has contributed to more than 180 papers in international journals and textbooks and is an editorial board member of the Journal of Thrombosis and Haemostasis, and Deputy Editor of Thrombosis Journal. His research focuses on the pathophysiology of thrombosis and inflammation-coagulation interactions in experimental models of disease as well as in clinical studies. He currently combines clinical and experimental research in his principal investigator position in the Cardiovascular Research Institute Maastricht (CARIM), focusing on thrombosis in cardiovascular disease.
 
Industrial partners
  • Philips Electronics Nederland BV  
  • Sanquin
  • Synapse BV
Academic partners
  • Academisch Medisch Centrum (AMC), Amsterdam, www.amc.uva.nl
  • Leids Universitair Centrum (LUMC), Leiden, www.lumc.nl
  • Maastricht University Medical Center (MUMC), Maastricht, www.azm.nl/IDEE, IDEE/ Klinische Epidemiologie en Medical Technology Assessment (KEMTA)
  • Universitair Medisch Centrum Utrecht (UMCU), Utrecht, www.umcutrecht.nl
The CTMM Incoag project will also receive additional contribution from the Netherlands Heart Foundation.
 
Status of the Incoag project end of 2009: PDF (download)
Incoag project presentation at the CTMM Annual Meeting 2010: PDF (download)
 
 
 
General
 
In response to the first call for project proposals in 2007, the Center for Translational Molecular Medicine (CTMM) announced on April 1, 2008, that nine first-call projects would receive research funding amounting to a total of 150 million Euro. On March 10, 2009, it announced that eight new project proposals, submitted in the fall of 2008 in response to the second call for proposals, will receive funding amounting to a total of almost another 100 million Euro.
 
All Dutch university medical centers, plus several universities, a broad spectrum of small and medium-sized enterprises, major industry leaders including Philips and DSM, and the Dutch Government are involved.
 
The funding is provided by the Dutch government, industry and academia. The research is focused firmly on the ‘translational’ aspects of molecular medicine so that results can be applied as quickly as possible to actual patient care.
 
Incoag is one of the projects from the second call.
 
 
 
26 November 2010
 
 
 
   
   
   


 
   

 

 

© CTMM, Center for Translational Molecular Medicine | Contact | Login | Disclaimer